TCM
MCRB icon

Tang Capital Management’s Seres Therapeutics MCRB Stock Holding History

Tang Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,921
Closed -$155K – 204
2025
Q2 		$155K Buy
13,921
+3,726
+37% +$32.8K 0.01% 198
2025
Q1 		$143K Buy
+10,195
New +$160K 0.01% 200
2024
Q4 		– Sell
-10,000
Closed -$189K – 189
2024
Q3 		$189K Sell
10,000
-110,356
-92% -$2.24M 0.01% 149
2024
Q2 		$1.74M Buy
120,356
+75,000
+165% +$1.25M 0.18% 82
2024
Q1 		$702K Sell
45,356
-44,288
-49% -$955K 0.07% 90
2023
Q4 		$2.51M Buy
+89,644
New +$2.35M 0.23% 84

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Tang Capital Management's MCRB Position: Q3 2025 in Review

Tang Capital Management sold out of Seres Therapeutics (MCRB) in Q3 2025, closing a stake of 13,921 shares — an estimated $155K sold.

Tang Capital Management first reported a position in MCRB in Q4 2023 and held it in 6 quarters. The position peaked at $2.51M in Q4 2023. 32 funds tracked by Wall St. Rank hold MCRB as of Q3 2025.

  • Tang Capital Management reported no remaining Seres Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Tang Capital Management sold 13,921 Seres Therapeutics shares in Q3 2025, an estimated $155K.
  • Tang Capital Management first reported a position in Seres Therapeutics in Q4 2023 and held it in 6 quarters.
  • Tang Capital Management's Seres Therapeutics position peaked at $2.51M in Q4 2023.
  • 32 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2025.

Based on Tang Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.